Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 465

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 465
---
 of products, including Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, and APOKYN, or any of our product candidates that receive regulatory approval;

•Substitution of our products in favor of generic versions of our products or competitors' products;

•Status of patent infringement lawsuits, if applicable;

•The filing of ANDAs by generic companies seeking approval to market generic versions of our products;

•Plans for, progress in, and results from clinical trials of our product candidates generally;

•FDA or international regulatory actions, including actions on regulatory applications for any of our product candidates;

•Announcements of new products, services or technologies, commercial relationships, acquisitions, or other events by us or our competitors;

•Market conditions and regulatory changes in the pharmaceutical and biotechnology sectors;

•Fluctuations in stock market prices and trading volumes of similar companies;

•Variations in our quarterly operating results;

•Changes in accounting principles;

•Litigation or public concern about the safety of our products and/or potential products;

•Fluctuations in our quarterly operating results;

•Deviations in our operating results from the estimates of securities analysts;

•Additions or departures of key personnel;

•Sales or purchases of large blocks of our common stock, including sales by our executive officers, directors, and significant stockholders;

•Changes in third-party coverage and reimbursement policies for our products and/or product candidates; and

•Discussion by us of our stock price in the financial or scientific press or investor communities.

The realization of any of the risks described in these "Risk Factors" could have a dramatic, material, and adverse impact on the market price of our common stock. In addition, class action litigation has often been instituted against companies whose securities have experienced periods of volatility. Any such litigation brought against us could result in substantial costs and a diversion of management attention, which could hurt our business, operating results, and financial condition.

Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could negatively impact the market price of our common stock.

Provisions in our certificate of incorporation and bylaws, as amended, may have the effect of delaying or preventing a change of control. These provisions include the following:

•Our board of directors is divided into three classes, serving staggered three-year terms, such that not all members of the board will be elected at one time. This staggered board structure prevents stockholders from replacing the entire board at a single stockholders'